b-12
San Francisco, CA, US
AI copilot platform for pharmaceutical and biotech companies that accelerates drug discovery by automating experimental planning and robotic execution.
Source: HealthTechAlpha
HealthTechAlpha provided this information. To learn more and get deep data on all digital health companies, please visit them here.
Visit HealthTechAlpha →Problem Statement
Compresses early-stage drug discovery timelines from years to months.
Core Technology
AI copilot platform that converts natural language inputs into experimental designs and executable robotic instructions and interfaces with laboratory robots from Chemspeed, Opentrons, and Unchained in a vendor-agnostic manner.
Key Differentiators
Achieved 30x speed gains in experimental timelines with pilot programs; Eliminates typical 8-12 iteration cycles in chemical discovery workflows; Maintains vendor-agnostic integration with Chemspeed, Opentrons, and Unchained robotic platforms
Company Info
- Business Model
- B2B SaaS
- Founded
- 2025
- Total Funding
- 3,300,000
- Website
- www.b12-labs.com
MedStartr Index Score
?What do you think of b-12?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.